Evaluation of the Achieve Mapping Catheter in cryoablation for XXXX : a prospective randomized trial.

@entity1 @entity129 @entity955
PURPOSE: The purpose of this study is to establish the role of Achieve Mapping Catheter in cryoablation for paroxysmal @entity955 (PAF) in a randomized trial. METHODS: A total of 102 @entity1 undergoing their first ablation for PAF were randomized at 2:1 to an Achieve- or Lasso-guided procedure. Study @entity1 were systematically followed up for 12  months with Holter monitoring. Primary study endpoint was acute procedure success. Secondary endpoint was clinical outcomes assessed by AF free at 6 and 12  months after the procedure. RESULTS: Of 102 @entity1 , 99  % of acute procedure success was achieved. Significantly shorter procedure duration with the Achieve-guided group than with the Lasso-guided group (118        18 vs. 129        21  min, p   <   0.05) was observed as was the duration of fluoroscopy (17        5 vs. 20        7  min, p   <   0.05) by subgroup analysis focused on procedures performed by experienced operators. In the whole study @entity1 , procedure and fluoroscopic durations were similar in the Achieve- (n   =   68) and Lasso-guided groups (n   =   34). Transient @entity129 weakening was equally prevalent with the Achieve and Lasso. No association was found between clinical outcomes and the mapping catheter used. The use of second-generation cryoballoon (n   =   68) reduced procedure time significantly compared to the first-generation balloon (n   =   34); more @entity1 were free of AF in the former than the latter group during follow-up. CONCLUSIONS: The use of the Achieve Mapping Catheter can reduce procedure and fluoroscopic durations compared with Lasso catheters in cryoablation for PAF after operators gained sufficient experience. The type of mapping catheter used does not affect procedure efficiency and safety by models of cryoballoon.
